Ascendia

  MARKET NEWS

Sanofi Completes Acquisition of Vigil Neuroscience
Evoke Pharma Announces Issuance of New Patent for GIMOTI With Extended Exclusivity to Late 2038
Cardurion Pharmaceuticals Completes Enrollment in Phase 2 Trials Evaluating a Novel PDE9 Inhibitor in Heart Failure
Moleculin Biotech Reports Promising Preclinical Data of Annamycin in Liver Cancer Treatment
Porosome Therapeutics Announces Breakthrough Alzheimer's Discoveries
Polpharma Biologics & Fresenius Kabi Sign Licensing Agreement for Proposed Vedolizumab Biosimilar
Axplora Announces Significant Investment at Vizag Site & FDA Inspection Success Across Indian Operations
Elicio Therapeutics Announces Positive Recommendation to Continue ELI-002 7P Randomized Phase 2 Study in Pancreatic Cancer Without Modifications to Final Analysis
SERB Pharmaceuticals Agrees to Acquire Y-mAbs Therapeutics
Yatiri Bio Acquires NGeneBioAI to Expand AI-Powered Proteomics Platform & Advance Precision Biomarker Discovery

  EXPERT CONTENT & RESOURCES

Kindeva e-Book: A Bridge to the Future: Our World-Class Site in Bridgeton

Kindeva e-Book: A Bridge to the Future: Our World-Class Site in Bridgeton

In this e-Book, you will learn about, the integrated capabilities of Bridgeton, MO, which eliminate the risks of fragmentation, the breadth of projects that Kindeva can support, our continuous investment in the facility to ensure it meets today’s demands and the needs of tomorrow, and the benefits of partnering with Kindeva.

Choosing the Right Particle for Your Nanomedicine Application

Choosing the Right Particle for Your Nanomedicine Application

Nanoparticles are revolutionizing the landscape of nanomedicine, enabling significant advancements in early detection, targeted drug delivery, disease monitoring, and imaging. Due to their nanoscale size, these particles….

EXECUTIVE INTERVIEW - Plus Therapeutics: Advancing Targeted Radiotherapeutics for Rare & Difficult-to-Treat Cancers

EXECUTIVE INTERVIEW - Plus Therapeutics: Advancing Targeted Radiotherapeutics for Rare & Difficult-to-Treat Cancers

Dr. Marc Hedrick, CEO of Plus Therapeutics, discusses the company’s targeted radiotherapeutic platform for central nervous system and solid tumor cancers and why internal radiation therapy offers patients a more advanced drug delivery solution compared to traditional external radiation therapy.

Closing the Access Gap in Pediatric Oncology & Why Neuroblastoma Families Are Still Struggling

Closing the Access Gap in Pediatric Oncology & Why Neuroblastoma Families Are Still Struggling

Neuroblastoma is a rare pediatric solid tumor that arises from immature nerve cells. It accounts for roughly 15% of childhood cancer deaths, despite being only 6%-10% of diagnoses. Nearly half of children are diagnosed with…

  FEATURED EDITORIAL

  COMPANY PROFILE

Vetter produces aseptically prefilled syringes, cartridges, vials and dual-chamber systems as a globally operating CDMO partner. We are a reliable, family-owned, independent company rooted in 75+ years of history. We do not manufacture our own drugs. We support our customers from the initial phases of clinical drug product development and filling to commercial manufacturing, device assembly and packaging, and lifecycle management. Over 80% of our active projects are biologics. Click here for more.

  WHITEPAPERS & WEBINARS

vytal webinar

WEBINAR - Vytal: The RTU Snap-Fit System for Container Closure Solutions – Setting the Standard for the Future

In recent decades, the landscape of parenteral drug production has undergone significant transformation, driven by the emergence of novel molecules and advanced therapies. The pharmaceutical industry has witnessed a notable shift towards biologics, mAbs, and cell-based therapies, which now represent some of the most successful pharmaceutical products globally.

WEBINAR ON DEMAND: Precision at Scale: Enabling Novel Therapeutics With Nanoparticle Manufacturing

WEBINAR ON DEMAND: Precision at Scale: Enabling Novel Therapeutics With Nanoparticle Manufacturing

Watch this on-demand webinar to learn about the key steps and considerations in bringing novel nanoparticle-based therapeutics from early R&D to commercial stages. Drawing from our 20 years of experience in the CDMO space, we cover critical topics unique to nanomaterials…..

  WHITEPAPERS & WEBINARS

WHITEPAPER - OXYCAPT™: Multilayer Plastic Vial: An Optimal Primary Container for Drug Products Transported With Dry Ice

WHITEPAPER - OXYCAPT™: Multilayer Plastic Vial: An Optimal Primary Container for Drug Products Transported With Dry Ice

Providing Ideal Protection for Invaluable Drug Products, Including Cell and Gene Therapy Products

Product Introduction of OXYCAPT™

OXYCAPT™ is a multilayer plastic vial and syringe, consisting of three layers made from two types of resins.  The drug contact layer and …

WHITEPAPER - Unlock the Secrets of Spray Drying for Sticky APIs

WHITEPAPER - Unlock the Secrets of Spray Drying for Sticky APIs

It is widely reported that 40% of New Chemical Entities (NCEs) in the pharmaceutical industry are poorly soluble, leading to inadequate bioavailablity. Spray drying is one of the most promising particle engineering technologies used to overcome solubility issues in active …

WHITEPAPER - Continuous Flow - An Emerging Alternative

WHITEPAPER - Continuous Flow - An Emerging Alternative

Pharmaceutical companies have traditionally been risk-averse, often adopting safe and well-established processes due to the conservative stance of regulatory agencies on novel methodologies. However, with the increasing complexity of drug molecules and the demand for newer and harsher reaction conditions, …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

August 13 – Lyophilization Manufacturing
August 20 – Excipients